VP, Business Development, Oncology
Debi Watson is the head of the Oncology Business Development Group at Johnson & Johnson Innovation, Janssen Business Development, a position she has held since May 2013. In this role, she leads Business Development Strategy in coordination with Oncology R&D and Commercial leadership. Debi is responsible for all aspects of Licensing, Search and Evaluation, M&A and Alliance Management for the Janssen Oncology Therapeutic Area.
Under Debi’s leadership the oncology team has executed several important transactions including the recent BCMA CAR-T/Legend deal, niraparib/TESARO, Imetelstat/Geron, and two deals with MacroGenics. With her guidance, the oncology team manages several significant alliances including the Ibrutinib alliance with Pharmacyclics/Abbie and Daratumumab with Genmab.
Debi has over 20 years of experience in the Pharmaceutical Industry spanning multiple therapeutic areas. Prior to leading the oncology Business Development team, Debi led the Anti-Infective Business Development Group and completed several transactions in support of the HIV and HCV Disease Strategies. Earlier, she served as a transaction lead for the Research and Early Discovery group, where she led the efforts to outlicense de-prioritized assets, including a license/option deal with PPD/Furiex which was later acquired by Allergan. Debi also worked in the licensing group supporting the Neuroscience franchise and served in roles of increasing responsibility in the sales and marketing divisions of Janssen and Johnson & Johnson.
Debi graduated from the University of Connecticut in Storrs, CT.